Octreotide administration in diabetic rats: effects on renal hypertrophy and urinary albumin excretion.

Flyvbjerg A, Marshall SM, Frystyk J, Hansen KW, Harris AG, Orskov H

Kidney international1 Apr 1992Cited by 48 (Europe PMC)

PMID1513103DOI10.1038/ki.1992.124PepBankPUB-01513103

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, octreotide did not change body weight, food intake, blood glucose, urinary glucose, HbA1C, fructosamine, serum GH or creatinine clearance versus untreated rats.
In plain wordsIn diabetic rats, octreotide did not change the listed metabolic measures, growth hormone or creatinine clearance versus untreated rats.
Peptide
Octreotide
Outcome
No significant changeMetabolic measures, GH and creatinine clearance
Study
ratn: not reported in source
Streptozotocin-diabetic rats
Comparator
Untreated diabetic rats
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 micrograms twice daily · subcutaneous · six monthsAs given in this study (rat).
Source sentences
Summary
No differences were seen between the two diabetic groups in respect to body weight, food intake, blood glucose levels, urinary glucose output, hemoglobin A1C(HbA1C), fructosamine, serum growth hormone (rGH) or creatinine clearance
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the long-term effects of SMS on renal hypertrophy and urinary albumin excretion (UAE), streptozotocin-diabetic and non-diabetic rats were treated with two daily subcutaneous injections of SMS (100 micrograms x 2) for six months.
Summary · context
Untreated diabetic and non-diabetic animals were used as reference groups.
Report a problemFND-0151310301
02AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, octreotide reduced kidney weight to 896 +/- 36 versus 1000 +/- 24 mg in untreated rats (P less than 0.02).
In plain wordsIn diabetic rats, octreotide reduced kidney weight versus untreated rats.
Peptide
Octreotide
Outcome
DecreaseDiabetic kidney weight
Study
ratn: not reported in source
Streptozotocin-diabetic rats
Comparator
Untreated diabetic rats
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 micrograms twice daily · subcutaneous · six monthsAs given in this study (rat).
Source sentences
Summary
but kidney weight (896 +/- 36 vs. 1000 +/- 24 mg, P less than 0.02)
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the long-term effects of SMS on renal hypertrophy and urinary albumin excretion (UAE), streptozotocin-diabetic and non-diabetic rats were treated with two daily subcutaneous injections of SMS (100 micrograms x 2) for six months.
Summary · context
Untreated diabetic and non-diabetic animals were used as reference groups.
Report a problemFND-0151310302
03AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, octreotide reduced urinary albumin excretion to 417 +/- 131 versus 1098 +/- 187 micrograms/24 hr (P less than 0.02).
In plain wordsIn diabetic rats, octreotide reduced urinary albumin excretion versus untreated rats.
Peptide
Octreotide
Outcome
DecreaseDiabetic urinary albumin excretion
Study
ratn: not reported in source
Streptozotocin-diabetic rats
Comparator
Untreated diabetic rats
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 micrograms twice daily · subcutaneous · six monthsAs given in this study (rat).
Source sentences
Summary
UAE (417 +/- 131 vs. 1098 +/- 187 micrograms/24 hr, P less than 0.02)
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the long-term effects of SMS on renal hypertrophy and urinary albumin excretion (UAE), streptozotocin-diabetic and non-diabetic rats were treated with two daily subcutaneous injections of SMS (100 micrograms x 2) for six months.
Summary · context
Untreated diabetic and non-diabetic animals were used as reference groups.
Report a problemFND-0151310303
04AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, octreotide reduced kidney IGF-I to 167 +/- 16 versus 239 +/- 17 ng/g in untreated rats (P less than 0.01).
In plain wordsIn diabetic rats, octreotide reduced kidney IGF-I versus untreated rats.
Peptide
Octreotide
Outcome
DecreaseDiabetic kidney IGF-I
Study
ratn: not reported in source
Streptozotocin-diabetic rats
Comparator
Untreated diabetic rats
Outcome group
Growth hormone and IGF-1 · Kidney and urinary
Studied dose
100 micrograms twice daily · subcutaneous · six monthsAs given in this study (rat).
Source sentences
Summary
kidney insulin-like growth factor I (IGF-I) (167 +/- 16 vs. 239 +/- 17 ng/g, P less than 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the long-term effects of SMS on renal hypertrophy and urinary albumin excretion (UAE), streptozotocin-diabetic and non-diabetic rats were treated with two daily subcutaneous injections of SMS (100 micrograms x 2) for six months.
Summary · context
Untreated diabetic and non-diabetic animals were used as reference groups.
Report a problemFND-0151310304
05AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, octreotide reduced serum IGF-I to 301 +/- 26 versus 407 +/- 17 micrograms/liter (P less than 0.01).
In plain wordsIn diabetic rats, octreotide reduced serum IGF-I versus untreated rats.
Peptide
Octreotide
Outcome
DecreaseDiabetic serum IGF-I
Study
ratn: not reported in source
Streptozotocin-diabetic rats
Comparator
Untreated diabetic rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms twice daily · subcutaneous · six monthsAs given in this study (rat).
Source sentences
Summary
serum IGF-I (301 +/- 26 vs. 407 +/- 17 micrograms/liter, P less than 0.01) were all reduced in the SMS-treated diabetic animals when compared to the untreated diabetic group.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the long-term effects of SMS on renal hypertrophy and urinary albumin excretion (UAE), streptozotocin-diabetic and non-diabetic rats were treated with two daily subcutaneous injections of SMS (100 micrograms x 2) for six months.
Summary · context
Untreated diabetic and non-diabetic animals were used as reference groups.
Report a problemFND-0151310305
06AnimalAnimal study (in vivo)Efficacy outcome
In non-diabetic rats, octreotide reduced body weight to 274 +/- 3 versus 293 +/- 5 g (P less than 0.01).
In plain wordsIn non-diabetic rats, octreotide reduced body weight versus untreated controls.
Peptide
Octreotide
Outcome
DecreaseNon-diabetic body weight
Study
ratn: not reported in source
Non-diabetic rats
Comparator
Untreated non-diabetic rats
Outcome group
Body weight · Metabolic and weight
Studied dose
100 micrograms twice daily · subcutaneous · six monthsAs given in this study (rat).
Source sentences
Summary
In non-diabetic rats SMS reduced body weight (274 +/- 3 vs. 293 +/- 5 g, P less than 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the long-term effects of SMS on renal hypertrophy and urinary albumin excretion (UAE), streptozotocin-diabetic and non-diabetic rats were treated with two daily subcutaneous injections of SMS (100 micrograms x 2) for six months.
Summary · context
Untreated diabetic and non-diabetic animals were used as reference groups.
Report a problemFND-0151310306
07AnimalAnimal study (in vivo)Efficacy outcome
In non-diabetic rats, octreotide reduced kidney weight to 695 +/- 9 versus 764 +/- 17 mg (P less than 0.01).
In plain wordsIn non-diabetic rats, octreotide reduced kidney weight versus untreated controls.
Peptide
Octreotide
Outcome
DecreaseNon-diabetic kidney weight
Study
ratn: not reported in source
Non-diabetic rats
Comparator
Untreated non-diabetic rats
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 micrograms twice daily · subcutaneous · six monthsAs given in this study (rat).
Source sentences
Summary
kidney weight (695 +/- 9 vs. 764 +/- 17 mg, P less than 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the long-term effects of SMS on renal hypertrophy and urinary albumin excretion (UAE), streptozotocin-diabetic and non-diabetic rats were treated with two daily subcutaneous injections of SMS (100 micrograms x 2) for six months.
Summary · context
Untreated diabetic and non-diabetic animals were used as reference groups.
Report a problemFND-0151310307
08AnimalAnimal study (in vivo)Efficacy outcome
In non-diabetic rats, octreotide reduced urinary albumin excretion to 83 +/- 29 versus 364 +/- 114 micrograms/24 hr (P less than 0.02).
In plain wordsIn non-diabetic rats, octreotide reduced urinary albumin excretion versus untreated controls.
Peptide
Octreotide
Outcome
DecreaseNon-diabetic urinary albumin excretion
Study
ratn: not reported in source
Non-diabetic rats
Comparator
Untreated non-diabetic rats
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 micrograms twice daily · subcutaneous · six monthsAs given in this study (rat).
Source sentences
Summary
UAE (83 +/- 29 vs. 364 +/- 114 micrograms/24 hr, P less than 0.02)
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the long-term effects of SMS on renal hypertrophy and urinary albumin excretion (UAE), streptozotocin-diabetic and non-diabetic rats were treated with two daily subcutaneous injections of SMS (100 micrograms x 2) for six months.
Summary · context
Untreated diabetic and non-diabetic animals were used as reference groups.
Report a problemFND-0151310308
09AnimalAnimal study (in vivo)Efficacy outcome
In non-diabetic rats, octreotide reduced kidney IGF-I to 202 +/- 12 versus 280 +/- 12 ng/g (P less than 0.01).
In plain wordsIn non-diabetic rats, octreotide reduced kidney IGF-I versus untreated controls.
Peptide
Octreotide
Outcome
DecreaseNon-diabetic kidney IGF-I
Study
ratn: not reported in source
Non-diabetic rats
Comparator
Untreated non-diabetic rats
Outcome group
Growth hormone and IGF-1 · Kidney and urinary
Studied dose
100 micrograms twice daily · subcutaneous · six monthsAs given in this study (rat).
Source sentences
Summary
kidney IGF-I (202 +/- 12 vs. 280 +/- 12 ng/g, P less than 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the long-term effects of SMS on renal hypertrophy and urinary albumin excretion (UAE), streptozotocin-diabetic and non-diabetic rats were treated with two daily subcutaneous injections of SMS (100 micrograms x 2) for six months.
Summary · context
Untreated diabetic and non-diabetic animals were used as reference groups.
Report a problemFND-0151310309
10AnimalAnimal study (in vivo)Efficacy outcome
In non-diabetic rats, octreotide reduced serum IGF-I to 428 +/- 21 versus 601 +/- 54 micrograms/liter (P less than 0.01).
In plain wordsIn non-diabetic rats, octreotide reduced serum IGF-I versus untreated controls.
Peptide
Octreotide
Outcome
DecreaseNon-diabetic serum IGF-I
Study
ratn: not reported in source
Non-diabetic rats
Comparator
Untreated non-diabetic rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms twice daily · subcutaneous · six monthsAs given in this study (rat).
Source sentences
Summary
serum IGF-I (428 +/- 21 vs. 601 +/- 54 micrograms/liter, P less than 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the long-term effects of SMS on renal hypertrophy and urinary albumin excretion (UAE), streptozotocin-diabetic and non-diabetic rats were treated with two daily subcutaneous injections of SMS (100 micrograms x 2) for six months.
Summary · context
Untreated diabetic and non-diabetic animals were used as reference groups.
Report a problemFND-0151310310
11AnimalAnimal study (in vivo)Efficacy outcome
In non-diabetic rats, octreotide reduced serum GH to 67 +/- 6 versus 126 +/- 27 micrograms/liter (P less than 0.05).
In plain wordsIn non-diabetic rats, octreotide reduced serum growth hormone versus untreated controls.
Peptide
Octreotide
Outcome
DecreaseNon-diabetic serum GH
Study
ratn: not reported in source
Non-diabetic rats
Comparator
Untreated non-diabetic rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms twice daily · subcutaneous · six monthsAs given in this study (rat).
Source sentences
Summary
serum rGH (67 +/- 6 vs. 126 +/- 27 micrograms/liter, P less than 0.05) when compared to untreated controls.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the long-term effects of SMS on renal hypertrophy and urinary albumin excretion (UAE), streptozotocin-diabetic and non-diabetic rats were treated with two daily subcutaneous injections of SMS (100 micrograms x 2) for six months.
Summary · context
Untreated diabetic and non-diabetic animals were used as reference groups.
Report a problemFND-0151310311
12AnimalAnimal study (in vivo)Efficacy outcome
In non-diabetic rats, kidney weight relative to body weight did not differ between octreotide and untreated controls.
In plain wordsIn non-diabetic rats, relative kidney weight did not differ between octreotide and untreated controls.
Peptide
Octreotide
Outcome
No significant changeRelative kidney weight, non-diabetic rats
Study
ratn: not reported in source
Non-diabetic rats
Comparator
Untreated non-diabetic rats
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 micrograms twice daily · subcutaneous · six monthsAs given in this study (rat).
Source sentences
Summary
When kidney weights were expressed in relation to body weight no difference was found between SMS-treated and untreated controls, while the difference between SMS-treated and untreated diabetic animals was still present (P less than 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the long-term effects of SMS on renal hypertrophy and urinary albumin excretion (UAE), streptozotocin-diabetic and non-diabetic rats were treated with two daily subcutaneous injections of SMS (100 micrograms x 2) for six months.
Summary · context
Untreated diabetic and non-diabetic animals were used as reference groups.
Report a problemFND-0151310312
13AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, reduced kidney weight with octreotide remained after adjustment for body weight (P less than 0.01).
In plain wordsIn diabetic rats, octreotide reduced kidney weight relative to body weight versus untreated rats.
Peptide
Octreotide
Outcome
DecreaseRelative kidney weight, diabetic rats
Study
ratn: not reported in source
Streptozotocin-diabetic rats
Comparator
Untreated diabetic rats
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 micrograms twice daily · subcutaneous · six monthsAs given in this study (rat).
Source sentences
Summary
When kidney weights were expressed in relation to body weight no difference was found between SMS-treated and untreated controls, while the difference between SMS-treated and untreated diabetic animals was still present (P less than 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the long-term effects of SMS on renal hypertrophy and urinary albumin excretion (UAE), streptozotocin-diabetic and non-diabetic rats were treated with two daily subcutaneous injections of SMS (100 micrograms x 2) for six months.
Summary · context
Untreated diabetic and non-diabetic animals were used as reference groups.
Report a problemFND-0151310313

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.